JP2015525239A - 新規カベルゴリン誘導体 - Google Patents

新規カベルゴリン誘導体 Download PDF

Info

Publication number
JP2015525239A
JP2015525239A JP2015518385A JP2015518385A JP2015525239A JP 2015525239 A JP2015525239 A JP 2015525239A JP 2015518385 A JP2015518385 A JP 2015518385A JP 2015518385 A JP2015518385 A JP 2015518385A JP 2015525239 A JP2015525239 A JP 2015525239A
Authority
JP
Japan
Prior art keywords
alkyl
substituted
hydrogen
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015518385A
Other languages
English (en)
Japanese (ja)
Inventor
ジャン，ジエン
アーマー，トーマス・エイ
Original Assignee
マップ・ファーマシューティカルズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マップ・ファーマシューティカルズ・インコーポレイテッド filed Critical マップ・ファーマシューティカルズ・インコーポレイテッド
Publication of JP2015525239A publication Critical patent/JP2015525239A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
    • C07D457/06—Lysergic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2015518385A 2012-06-22 2012-06-22 新規カベルゴリン誘導体 Pending JP2015525239A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/043687 WO2013191704A1 (en) 2012-06-22 2012-06-22 Novel cabergoline derivatives

Publications (1)

Publication Number Publication Date
JP2015525239A true JP2015525239A (ja) 2015-09-03

Family

ID=49769156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015518385A Pending JP2015525239A (ja) 2012-06-22 2012-06-22 新規カベルゴリン誘導体

Country Status (11)

Country Link
EP (1) EP2863747A4 (zh)
JP (1) JP2015525239A (zh)
CN (1) CN104822264A (zh)
AU (1) AU2012382929A1 (zh)
BR (1) BR112014031945A2 (zh)
CA (1) CA2876321A1 (zh)
HK (1) HK1208997A1 (zh)
IL (1) IL236310A0 (zh)
RU (1) RU2014153672A (zh)
SG (1) SG11201408567PA (zh)
WO (1) WO2013191704A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514372A (ja) * 2018-02-21 2021-06-10 アダムド ファーマ エス．アー．Ａｄａｍｅｄ Ｐｈａｒｍａ Ｓ．Ａ． デュアルの５−ｈｔ２ａおよび５−ｈｔ６受容体アンタゴニストとしての新しいインドールおよびベンゾイミダゾール誘導体

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428745A (zh) * 2015-01-20 2017-12-01 Xoc制药股份有限公司 麦角灵化合物及其用途
CN106866656A (zh) * 2017-02-28 2017-06-20 西南交通大学 一类麦角碱衍生物及其在预防和治疗精神疾病的用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
JPH02142790A (ja) * 1988-07-15 1990-05-31 Schering Ag ２−置換エルゴリン、それを含有するパーキンソン病を治療するための医薬品、ならびに当該化合物を製造するための方法および中間物質
JPH03505587A (ja) * 1989-04-21 1991-12-05 シエーリング　アクチエンゲゼルシヤフト ８β―置換されたエルゴリン、その製法及びその使用
EP1464644A1 (en) * 2003-03-31 2004-10-06 MeRaD Pharmaceuticals Limited Ergoline derivatives
WO2005085243A2 (en) * 2004-03-04 2005-09-15 Richter Gedeon Vegyészeti Gyár Rt. Process for the preparation of cabergoline
JP2006516596A (ja) * 2003-02-05 2006-07-06 ファルマシア イタリア ソチエタ ペル アツィオニ 偏頭痛の予防治療のためのカベルゴリン

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005176A1 (en) * 1993-08-18 1995-02-23 Alcon Laboratories, Inc. Use of ergoline derivatives for the treatment of glaucoma
CZ287176B6 (cs) * 1997-10-03 2000-10-11 Galena A. S. Způsob přípravy ergolinových derivátů
WO2006097345A1 (en) * 2005-03-17 2006-09-21 Synthon Argentina S.A. Improved process for making cabergoline
GB0511060D0 (en) * 2005-05-31 2005-07-06 Novartis Ag Organic compounds
EP2083008A1 (en) * 2007-12-07 2009-07-29 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
WO2010081036A2 (en) * 2009-01-09 2010-07-15 President And Fellows Of Harvard College Fluorine containing compounds and methods of use thereof
AU2010237100A1 (en) * 2009-04-15 2011-10-27 Astrazeneca Ab Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as Alzheimer's disease
CA2859175A1 (en) * 2011-12-21 2013-06-27 Map Pharmaceuticals, Inc. Novel neuromodulatory compounds

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
JPH02142790A (ja) * 1988-07-15 1990-05-31 Schering Ag ２−置換エルゴリン、それを含有するパーキンソン病を治療するための医薬品、ならびに当該化合物を製造するための方法および中間物質
JPH03505587A (ja) * 1989-04-21 1991-12-05 シエーリング　アクチエンゲゼルシヤフト ８β―置換されたエルゴリン、その製法及びその使用
JP2006516596A (ja) * 2003-02-05 2006-07-06 ファルマシア イタリア ソチエタ ペル アツィオニ 偏頭痛の予防治療のためのカベルゴリン
EP1464644A1 (en) * 2003-03-31 2004-10-06 MeRaD Pharmaceuticals Limited Ergoline derivatives
WO2005085243A2 (en) * 2004-03-04 2005-09-15 Richter Gedeon Vegyészeti Gyár Rt. Process for the preparation of cabergoline

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ASHFORD, SCOTT W. ET AL.: "A Practical Synthesis of Cabergoline", THE JOURNAL OF ORGANIC CHEMISTRY, vol. Volume 67, Issue 20, JPN6016023265, 2002, pages 7147 - 7150, ISSN: 0003341677 *
BRAMBILLA, ENZO: "Synthesis and nidation inhibitory activity of a new class of ergoline derivatives", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. Volume 24, Issue 4, JPN6016023269, 1989, pages 421 - 426, ISSN: 0003341675 *
KEKEWSKA, ALEXANDRA ET AL.: "The Bulky N(6) Substituent of Cabergoline Is Responsible for Agonism of This Drug at 5-Hydroxytrypta", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 338, no. 1, JPN6016023268, 2011, pages 381 - 391, XP055228644, ISSN: 0003341674, DOI: 10.1124/jpet.111.181255 *
MANTEGANI, SERGIO ET AL.: "Serotonergic Ergoline Derivatives", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. Volume 8, Issue 9, JPN6016023266, 1998, pages 1117 - 1122, ISSN: 0003341678 *
MIYAGI, MASAHARU ET AL.: "Dopamine Receptor Affiniteis in Vitro and Stereotypic Activities in Vivo of Cabergoline in Rats", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 19, no. 9, JPN6016023263, 1996, pages 1210 - 1213, ISSN: 0003341676 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514372A (ja) * 2018-02-21 2021-06-10 アダムド ファーマ エス．アー．Ａｄａｍｅｄ Ｐｈａｒｍａ Ｓ．Ａ． デュアルの５−ｈｔ２ａおよび５−ｈｔ６受容体アンタゴニストとしての新しいインドールおよびベンゾイミダゾール誘導体
JP7200258B2 (ja) 2018-02-21 2023-01-06 アダムド ファーマ エス．アー． デュアルの５－ｈｔ２ａおよび５－ｈｔ６受容体アンタゴニストとしての新しいインドールおよびベンゾイミダゾール誘導体

Also Published As

Publication number Publication date
EP2863747A4 (en) 2015-12-23
BR112014031945A2 (pt) 2017-06-27
WO2013191704A1 (en) 2013-12-27
AU2012382929A1 (en) 2015-02-05
IL236310A0 (en) 2015-02-26
HK1208997A1 (zh) 2016-03-24
EP2863747A1 (en) 2015-04-29
CA2876321A1 (en) 2013-12-27
RU2014153672A (ru) 2016-08-10
CN104822264A (zh) 2015-08-05
SG11201408567PA (en) 2015-02-27

Similar Documents

Publication Publication Date Title
JP2014517076A (ja) 新規のフルオロエルゴリン類似体
JP6856532B2 (ja) エルゴリン化合物およびその使用
JP2016503795A (ja) 新規メチセルジド誘導体
JP2016503796A (ja) フルオロエルゴリン誘導体およびその使用
US9012640B2 (en) Cabergoline derivatives
US8946420B2 (en) Neuromodulatory compounds
US8722699B2 (en) Iso-ergoline derivatives
US9777016B2 (en) Isoergoline compounds and uses thereof
JP2015525239A (ja) 新規カベルゴリン誘導体
JP5840143B2 (ja) ニコチン性アセチルコリン受容体モジュレーター
US10407437B2 (en) Camptothecin derivatives and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150619

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170207